RESPONSIBILITY
We are committed to achieving our goal of improving the patient experience while operating in a sustainable, socially responsible manner. This commitment is consistent with our core values, which provide us with a framework for how we can deliver benefits for patients, employees, the environment, and local communities.
We provide, support, or sponsor:
We provide, support or sponsor:
Halozyme is committed to compliance with all applicable federal, state and local laws prohibiting unlawful considerations of race, religion, color, national origin, sex, sexual orientation, gender identity, age, disability, marital status or any other protected classification. Our goal is to maintain and grow our inclusive workplace and assure we have a work environment free from discrimination and harassment of any kind, including sexual harassment, racism, and discrimination based on gender or sexual orientation.
We integrate DE&I holistically into Halozyme’s core processes to ensure that it’s not a stand-alone initiative but is an intrinsic part of the organizational DNA. We continually work to build a diverse team that reflects the rich tapestry of global talent, united by a shared passion for making a positive impact on the lives of patients and their families.
We embrace and celebrate the unique talents, backgrounds, and perspectives each team member brings to the table, recognizing that diversity is a catalyst for innovation. In line with our commitment, we have adopted the Biotechnology Innovation Organization’s principles on workforce development, diversity, and inclusion. These principles guide our strategies to foster a workplace culture that nurtures creativity, collaboration, and excellence.
As of December 1, 2023, our dedication to these principles has resulted in a diverse and inclusive employee base. Specifically:
As part of our Elevate leadership training curriculum, we reinforce key DE&I topics with our leaders to provide them with the tools and training they need to support our DE&I efforts. Leaders learn how to prevent unconscious bias and promote trust and psychological safety, among other topics.
While we are proud of our achievements in creating a diverse and inclusive workforce, we recognize that fostering diversity is an ongoing journey. By fostering a culture that values and leverages the diverse strengths of our team, we believe we are better positioned to drive innovation, improve patient outcomes, and contribute meaningfully to the healthcare industry.
We have adopted the Biotechnology Innovation Organization’s principles on workforce development, diversity and inclusion, which are listed below:
Halozyme has established a compliance reporting mechanism intended to supplement, not replace, other channels for communicating questions or concerns within the organization. A company independent of Halozyme staffs this hotline, which may be used anonymously to report violations or suspected violations of the law. The hotline may be accessed by calling 855-350-9391, online at http://www.halozyme.ethicspoint.com, or by directly contacting the Audit Committee chairperson by e-mail at: ACChair@halozyme.com.
Halozyme Therapeutics, Inc. Annual Declaration pursuant to the California Health and Safety Code§§ 119400 -119402 (CA Senate Bill 1765)
Section 119402 of the California Health & Safety Code requires a pharmaceutical company to adopt a Comprehensive Compliance Program that is in accordance with the U.S. Department of Health and Human Services, Office of Inspector General’s (“OIG”) “Compliance Program Guidance for Pharmaceutical Manufacturers”(“OIG Compliance Guidance”), and include policies for complying with the Pharmaceutical Research and Manufacturers of America Code (“PhRMA Code”). Further, the law requires that the Comprehensive Compliance Program include an annual limit for certain items and activities given to healthcare professionals covered by this California law. Finally, the law requires that each manufacturer make its Comprehensive Compliance Program and an annual declaration of compliance publicly available.
Halozyme Pharmaceuticals, Inc. (Halozyme or the Company) has invested significant time and resources to the development of its policies, procedures and processes that make up its Comprehensive Compliance Program (the Program). Simultaneously, the Program is designed to identify potential non-compliance through audit and employee reporting, and provide a mechanism for investigation and resolution of such situations. Resolution, when appropriate, may involve disciplinary action up to and including termination of employment. The Program also includes an annual spend limit of $2000 for items and activities provided to healthcare professionals in California.
In developing related policies, procedures and processes, Halozyme reviewed the OIG Compliance Guidance and the PhRMA Code, and believes that its Program is consistent with a reasonable interpretation of those guidelines and is in compliance with other applicable laws and regulations as of the date of this declaration. Based upon Halozyme’s good faith understanding of applicable laws and regulations, and to the best of its knowledge, Halozyme is in substantial compliance with its Compliance Program and the California law.
Anyone wishing to obtain a copy of Halozyme’s Corporate Compliance Program Overview, the Code of Conduct or a copy of this Declaration can call 858.794.8889 or email info@halozyme.com.
Halozyme Therapeutics Inc. complies with all applicable tax laws, regulations, and tax compliance requirements. Halozyme and its affiliated subsidiaries are primarily domestic with no material international filing obligations. Halozyme regularly reviews its tax filing requirements and those of its affiliated subsidiaries and discloses income and non-income taxes paid in our publicly filed financial statements.
